Chiesi believes that true ‘sustainability’ can only be achieved with a broad array of projects that protect both our patients and the planet. As such this defines our actions, and the way that we do business. In recognition to our commitment to sustainability, Chiesi is proud to have been recognised as a certified B Corp and committed in 2019 to becoming carbon neutral by the end of 2035 well ahead of the 2050 target set out in the Paris agreement – and 15 years ahead of the UK national target1,2.
This podcast series aims to demystify the various terminology used when discussing carbon neutrality in relation to sustainable respiratory care, and explores the carbon footprint associated with sustainable respiratory care and what the health care community can do to be more environmentally focussed without limiting patient choice.
1. Chiesi Group calls for #ActionOverWords in the fight against climate change. Available at: https://www.chiesi.uk.com/img/news/646_chiesi-group-microsite-press-release.pdf
2. Legislation.gov.uk. The Climate Change Act 2008 (2050 Target Amendment)Order 2019. Available at: https://www.legislation.gov.uk/ukdsi/2019/9780111187654
01: Demystifying the differences between carbon offsetting and net zero
Asher Minns and Moe Hanslot (Chiesi) discuss the differences carbon neutrality, carbon offsetting and net zero, sharing examples of best practices and details around Chiesi’s journey to net zero.
02: What is B-Corp and what does it mean?
Anne Oliver and Matt Wiggetts (Chiesi) discuss the concept of B-Corp within the pharmaceutical industry, and share details of what B-Corp means to Chiesi.
03: What are the relevant considerations for inhaler recycling?
Carol Stonham and Moe Hanslot (Chiesi) explore inhaler recycling in detail, touching on the schemes currently available and advice on how to set up schemes in localities across the UK.
04: Changing role of SABAs in asthma care and patient care
Prof Omar Usmani and Prof Jennifer Quint discuss the changing role of SABAs in asthma care, and the importance of patient choice in choosing the right device for the right patient.
05: What is the carbon footprint of an inhaler?
Dr Toby Capstick and Prof Omar Usmani discuss how the carbon footprint of an inhaler is measured, and explore the challenges around interpretation of this information.
Asthma is a condition which affects different patients in different ways and can be challenging to manage. The national review of Asthma deaths1 outlines 19 recommendations for Asthma care. This podcast series aims to discuss the first-hand experiences of the healthcare community working with some of these recommendations, and explores useful ideas on implementation with the aim of achieving enhanced asthma care.
1. National review of Asthma Deaths. Accessed at https://www.rcplondon.ac.uk/projects/national-review-asthma-deaths
01: The emerging role of the pharmacist in asthma care
Grainne D’Ancona and Ms Alicia Piwko discuss the emerging role of the pharmacist in asthma care, and a new adult structured medicine review template available to aid consultations.
02: What is uncontrolled asthma, and what can we do about it?
Grainne D’Ancona and Dr Hitasha Rupani discuss the impact of uncontrolled asthma and explore how the HASTE tool could be used to enhance consultations.
03: Tackling SABA overuse
Dr Richard Russell and Dr Michael Crooks discuss the significant challenge of SABA overuse, exploring how much is too much and when to consider referring a patient.
04: Right Patient, Right Device
Dr Richard Russell and Dr Toby Capstick discuss the importance of joint decision making when choosing an inhaler, exploring the factors to consider when choosing the right device for the right patient.
05: The importance of early diagnosis in asthma
Dr Richard Russell and Dr Fiona Musgrove discuss the importance of early diagnosis of asthma and explore some useful tools to aid diagnosis.
06: How to identify adherence in patients with asthma
Grainne D’Ancona and Dr Brian Kent discuss the importance of adherence, sharing ideas on how to identify challenges with adherence and suggest some strategies on how to address it.
07: Clinical remission
Dom Shaw and Hitasha Rupani discuss the concept of clinical remission, whether this should be the goal in asthma management and if it is an achievable goal.
Risk prediction in asthma
Release date: December 7, 2023
Optimising communication between primary and secondary care
Release date: January 8, 2024
Conditions that mimic asthma
Release date: February 7, 2024
Release date: March 7, 2024
Navigating QOF for a good asthma review
Release date: April 8, 2024
Managing COPD is much more than ensuring a patient is prescribed inhalers. It requires a holistic approach to managing the condition, alongside other co- or multimorbidities the patient may have. In this podcast series, Chiesi have brought together the views from a wide range of healthcare professionals (hospital consultant, GP with specialist interest in respiratory, specialist nurse, specialist pharmacists, physiotherapist & respiratory epidemiologist) to explore topics that may help to optimise the care provided to COPD patients.
01: Why are exacerbations missed opportunities to optimise treatment
Prof John Hurst and Dr Steve Holmes discuss how exacerbations can be used to optimise treatment regimes and care for COPD patients.
02: How to offer pulmonary rehabilitation to your patients
Prof John Hurst and Ms Eleanor Lyons discuss the importance of pulmonary rehabilitation in COPD management, and the benefits that it can offer patients.
03: Finding the missing millions
Prof John Hurst and Prof Jennifer Quint discuss the challenges of early diagnosis of COPD, and explore the importance of getting the diagnosis (and coding) right.
04: Unconscious Bias – how to address intimate activity in patients wit...
Dr Steve Holmes and Ms Jane Scullion respectfully raise awareness of unconscious bias related to intimate activity in patients with COPD and explore how this can be addressed.
05: Multimorbidity in COPD – does it matter?
Prof John Hurst and Mr Garry McDonald discuss the commonest multimorbidities in patients with COPD, and explore the importance of addressing these within the management of COPD.
The first CFTR modulator became available on the NHS in December 2016 and was made available for around 5% of pwCF1. In 2022, around 90% of pwCF2 in the UK are suitable for CFTR modulator therapy.
Whilst there is no doubt CFTR modulators have positively and dramatically altered the disease pathway of cystic fibrosis3-5, there remains a level of uncertainty around how to manage the changing clinical picture of cystic fibrosis alongside these transformational medicines. This podcast series is designed to discuss some of the challenges of ‘Life alongside CFTR modulators.’
1. NHS clinical commissioning guidance 2015 Ivacaftor. Accessed at:
2. Cystic fibrosis trust 2021 registry report. Accessed at:
3. Cuevas-Ocaña S, Laselva O, Avolio J, Nenna R. The era of CFTR modulators: improvements made and remaining challenges. Breathe. 2020 Jun 1;16(2)
4. Middleton PG, Taylor-Cousar JL. Development of elexacaftor–tezacaftor–ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis. Expert Review of Respiratory Medicine. 2021 Jun 3;15(6):723-35
5. Lopes-Pacheco M. CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Frontiers in pharmacology. 2020 Feb 21;10:1662.
01: Breaking lifelong eating habits – impossible?
In this episode of ‘Life alongside CFTR modulators’, Prof Nick Simmonds and Joanna Snowball discuss how the conversation around diet and nutrition is changing and the need to adapt long established principles of nutritional management and develop new CF guidelines.
Where has all the mucus gone?
Release date: December 4, 2023
Transformational medicines: Challenges and opportunities for patients and...
Release date: January 8, 2024
CFTR modulators: Through the lens of the CF pharmacist
Release date: February 5, 2024
‘The new normal’ from the nurse perspective
Release date: March 4, 2024
Cystic fibrosis: Life in an era of novel therapies?
Release date: April 1, 2024
The management of neonatal complications are complex and require a holistic approach, particularly for preterm infants who may be more vulnerable. There are many clinical challenges to consider in the first 24 hours of life for a neonate and these complications require round-the-clock care from a team of clinical experts. Chiesi has therefore brought together a panel of consultant neonatologists with specific expertise in some of the clinical challenges that neonates face in their first 24 hours of life.
01: How best to keep the baby off the ventilator?
Dr David Sweet and Professor Charles Roehr explore different modes of respiratory support for preterm infants and discuss ways to prevent and minimise mechanical ventilation.
02: The importance of the late preterm population
Dr David Sweet and Professor Elaine Boyle discuss the importance of the late preterm population, why we should be more concerned about this cohort and how best to improve their outcomes.
03: Optimising delivery room management
Dr David Sweet and Professor Heike Rabe discuss optimising delivery room management, the importance of delayed cord clamping and the practicalities of this in the first minutes of life.
04: Neonatal transport – Tips & Tricks
Dr David Sweet and Dr Cath Harrison discuss the practical considerations and key aspects of neonatal transport, and how best to move babies between units.
05: Management of neonatal pulmonary hypertension
Dr David Sweet and Dr Nim Subhedar discuss the management of persistent foetal circulation and explore different treatment strategies for these babies.